Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

How Prevalent Is Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica?

Colm Kirby, MB, BCh, BAO, MRCPI, Rachael Flood, MB, BCh, BAO, MRCPI, Ronan Mullan, MB, BCh, BAO, MRCPI, Grainne Murphy, MB, BCh, BAO, MRCPI, & David Kane, MB, BCh, BAO, MRCPI  |  January 24, 2024

Background/Purpose

It has been reported that 20–50% of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). The natural history of ultrasound-defined subclinical GCA in PMR is not known.

Methods

Twenty-five newly diagnosed PMR patients who met a clinical diagnosis for PMR, verified by two rheumatologists, were examined by ultrasound. All six branches of the superficial temporal arteries and both axillary arteries were examined using a GE P9 device. Sonographic abnormalities considered indicative of vasculitis in the temporal arteries included the halo sign (see Figure 1) and non-compressible arteries with a thickened intima-media complex. In the axillary arteries, a halo sign and an intima-media thickness of >1.0 mm was considered positive. Follow-up consultations after one year were undertaken to review the clinical diagnoses.

FIGURE 1: Longitudinal view of the frontal branch of the superficial temporal artery, demonstrating a halo sign, as indicated by the anechoic region (yellow arrow) surrounding the inner Doppler (blue arrow) signal. (Click to enlarge.)

In the subclinical GCA group (identified on ultrasound), a PMR-dose steroid taper was used, with a prompt clinical response; a GCA-dose steroid taper was initiated for those who subsequently flared; and tocilizumab was initiated in the event of a second flare.

Results

The cohort consisted of 64% women (n=16) with a mean age of 67 years (range 50–84). 2012 ACR/EULAR classification criteria were met in 16 of 25 patients (primarily due to prior corticosteroid use in primary care, resulting in a normal erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Five patients (20%) were identified as having subclinical GCA on ultrasound. Of these, all five met 2012 ACR/EULAR PMR classification criteria; none met ACR GCA classification criteria. Temporal artery involvement was identified in those five patients, with axillary involvement in one of the five. The mean halo count was 3 (range 1–5), and the mean halo score was 21.2 (range 17–29). Two patients were managed with an initial PMR-dose of prednisolone but relapsed. Three patients were treated with an initial GCA-dose of steroids—all of whom relapsed.

At a median of 12 months follow-up, one of 20 (5%) of the PMR-only cohort had developed clinical signs of GCA. Five of five (100%) of the subclinical GCA cohort had developed a clinical diagnosis of GCA, with three requiring an increase in steroid dose and two requiring tocilizumab. At 12-month follow-up, none had developed ischemic complications.

Page: 1 2 | Single Page
Share: 

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch RheumVasculitis Tagged with:Giant Cell Arteritisgiant cell arteritis (GCA)glucocorticoid resistantimagingPMR FocusRheumPolymyalgia RheumaticaResearch Review

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Permanent Vision Loss in Late Giant Cell Arteritis

    October 18, 2018

    Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

    Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

    Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

    November 14, 2021

    Giant cell arteritis (GCA) is a granulomatous vasculitis of large- and medium-sized arteries, usually affecting the cranial branches of the aortic arch. It is the most common vasculitis, with the highest risk factor being age. Accurate diagnosis and prompt initiation of therapy are of great importance to prevent serious complications, with the most feared being…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences